|
|||||
|
|
Multiple sclerosis in Italy: cost-of-illness study |
|
| Authors: | F. Patti M. P. Amato M. Trojano C. Solaro A. Pappalardo V. Zipoli E. Portaccio D. Paolicelli A. Paolillo F. S. Mennini A. Marcellusi C. Ricci M. A. Battaglia |
| Affiliation: | 1. Multiple Sclerosis Centre Sicilia Region, First Neurology Clinic, University Hospital Catania, Catania, Italy 2. Department of Neurology, University of Florence, Florence, Italy 3. Department of Neurological and Psychiatric Sciences, University of Bari, Bari, Italy 4. Department of Neurology ASL3 Genovese, Genoa, Italy 5. Merck Serono Italy—An Affiliate of Merck KGA, Darmsdadt, Germany 6. CEIS Sanità (CHEM—Centre for Health Economics and Management), Faculty of Economics, University of Tor Vergata, Via Columbia, 2, 00133, Rome, Italy 7. Department of Physiopathology and Experimental Medicine and Public Health, University of Siena, Siena, Italy |
| Abstract: | This study estimates the direct costs of multiple sclerosis (MS) in Italy from the perspective of the National Health System. Patients diagnosed with MS for ≥1 year prior to study entry were included in the analysis; neurological disability was assessed using the Expanded Disability Status Scale (EDSS). Cost variables were analyzed according to: MS phenotype, disease course over the previous year and EDSS rating. A total of 510 patients were included in the analysis. Overall costs were significantly higher for relapsing-remitting MS and secondary progressive MS than for primary progressive MS (P < 0.05). Costs were higher for EDSS scores 0.0–3.5 and 4.0–6.0 than for scores > 6.0 (P < 0.05). The extrapolated data gave an estimated annual direct cost of MS per patient of €18,030. In conclusion, relapsing-remitting MS or secondary progressive MS phenotypes and lower estimated EDSS scores appear to be associated with higher costs. |
| Keywords: | |
| 本文献已被 SpringerLink 等数据库收录！ | |